The Relationship between the Sydney Classification and the First-Line Treatment Efficacy in Helicobacter-Associated Gastritis

Basit Öğe Kaydı
dc.authoridSENOCAK TASCI, ELIF/0000-0002-1686-1628
dc.contributor.authorTasci, Elif Senocak
dc.contributor.authorAkbas, Turkay
dc.date.accessioned2021-12-01T18:48:27Z
dc.date.available2021-12-01T18:48:27Z
dc.date.issued2020
dc.department[Belirlenecek]en_US
dc.description.abstractObjective: Helicobacter pyloriis responsible for a wide spectrum of diseases. Due to ease of use and access, the standard triple therapy is being used as first-line eradication in many areas. Intestinal metaplasia (IM) is a precancerous lesion that requires eradication therapy. Our aim is to investigate the effect of IM on the standard triple therapy success in H. pylori-positive patients. Subjects and Methods: The patients who were referred to Duzce University Hospital and Avrasya Hospital Gastroenterohepatology clinic between January 2014 and December 2016 and diagnosed with H. pylori-positive gastritis and underwent first-line eradication were evaluated retrospectively. Biopsy specimens were evaluated according to the updated Sydney system. All patients diagnosed with H. pylori started treatment with pantoprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days. Results: The mean age of 181 patients included in the study was 55.5 +/- 7.8. The success rate of H. pylori eradication was found to be low in severe chronic inflammation (p = 0.001). The success rate was found to be high among patients with no neutrophil activity (p = 0.009). As the intensity of IM increased, density of H. pylori was found to be decreased (p = 0.019). There was no correlation between glandular atrophy, IM, and H. pylori eradication success rate (p = 0.390 and p = 0.812). Conclusion: The severity of chronic inflammation is the most effective Sydney criteria for success of eradication, while the presence on IM does not have any effect.en_US
dc.identifier.doi10.1159/000508248
dc.identifier.endpage557en_US
dc.identifier.issn1011-7571
dc.identifier.issn1423-0151
dc.identifier.issue6en_US
dc.identifier.pmid32344409en_US
dc.identifier.scopus2-s2.0-85097968133en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage551en_US
dc.identifier.urihttps://doi.org/10.1159/000508248
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10535
dc.identifier.volume29en_US
dc.identifier.wosWOS:000598144300007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofMedical Principles And Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEradicationen_US
dc.subjectGastritisen_US
dc.subjectHelicobacter pylorien_US
dc.subjectIntestinal metaplasiaen_US
dc.subjectSydney classificationen_US
dc.subjectIntestinal Metaplasiaen_US
dc.subjectCampylobacter-Pylorien_US
dc.subjectEradicationen_US
dc.subjectSuccessen_US
dc.subjectAdherenceen_US
dc.subjectAreasen_US
dc.titleThe Relationship between the Sydney Classification and the First-Line Treatment Efficacy in Helicobacter-Associated Gastritisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10535.pdf
Boyut:
157.63 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu